Evidence map›Paper›PMID 41039592›Full record

ArticleHealth and quality of life outcomes2025

Health-related quality of life in patients with paediatric inflammatory bowel disease: IMPACT-III validation in Germany.

Aletta Boerkoel, Maresa Buchholz, Luisa Tischler, Niklas Weber, Wolfgang Hoffmann, Jan de Laffolie, Neeltje van den Berg, CEDATA Study Group

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Health and quality of life outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aletta BoerkoelInstitute for Community Medicine, University Medicine Greifswald, Ellernholzstrasse 1/2, DE-17487, Greifswald, Germany. aletta.boerkoel@med.uni-greifswald.de.
Maresa BuchholzGerman Center for Neurodegenerative Diseases, Site Greifswald/Rostock, Greifswald, Germany.
Luisa TischlerInstitute for Community Medicine, University Medicine Greifswald, Ellernholzstrasse 1/2, DE-17487, Greifswald, Germany.
Niklas WeberGerman Center for Neurodegenerative Diseases, Site Greifswald/Rostock, Greifswald, Germany.
Wolfgang HoffmannInstitute for Community Medicine, University Medicine Greifswald, Ellernholzstrasse 1/2, DE-17487, Greifswald, Germany.
Jan de LaffolieDepartment of General Paediatrics and Neonatology, University Children's Hospital, University Giessen, Giessen, Germany.
Neeltje van den BergInstitute for Community Medicine, University Medicine Greifswald, Ellernholzstrasse 1/2, DE-17487, Greifswald, Germany.
CEDATA Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealth related quality of life (HRQoL) in paediatric patients with inflammatory bowel disease (IBD) is typically measured using the patient reported outcome measure IMPACT-III. This measure has not yet been validated for German patients using the new 4-domain structure. As Germany has a comparatively high prevalence of paediatric IBD and as the IMPACT-III is the main HRQoL outcome measure in use, a validation in the German population is overdue.

objectiveTo validate the main patient reported outcome measure of health-related quality of life (HRQoL) in paediatric patients with inflammatory bowel disease (IBD) IMPACT-III in a German patient sample.

methodsClinical and HRQoL data was gathered in the CEDATA-GPGE registry. To determine the psychometric performance of the IMPACT-III in a German sample, distribution properties, reliability (Cronbach's alpha) and validity (correlations with clinical values; known-groups validity by age, sex, and self-rated health) were calculated. In addition, a confirmatory factor analysis was performed to determine the appropriateness of the factor structure.

resultsThe IMPACT-III was filled out by 221 patients (Female 46%; M

conclusionsThe German version of the IMPACT-III is a valid and reliable instrument to measure HRQoL in paediatric patients with IBD. The subscales of well-being and social functioning explain most of the total score. To interpret the subdomains of the IMPACT-III further research in a longitudinal design needs to be done, especially with age-related phrasing of the items.

trial registrationGerman Clinical Trials Register DRKS00015505. Registered on 22.01.2019 Inclusion of patients 01.03.2019; https://drks.de/search/en/trial/DRKS00015505 .

Indexed as

Inflammatory Bowel DiseasesPatient Reported Outcome MeasuresQuality of LifeAdolescentChildFemaleGermanyHumansMalePsychometricsReproducibility of ResultsSurveys and QuestionnairesHealth related quality of lifePaediatric inflammatory bowel diseasesPatient reported outcomesPsychometric testing

Identifiers

PMID41039592
PMCPMC12492618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.